GnRH antagonist in in vitro fertilization: where we are now.
Minerva Ginecol
; 55(5): 373-88, 2003 Oct.
Article
in En
| MEDLINE
| ID: mdl-14581880
ABSTRACT
This review focuses on the recent literature concerning the use of GnRH antagonists in ovulation induction for in vitro fertilization (IVF). The GnRH antagonists, ganirelix acetate (Orgalutran/Antagon) and cetrorelix (Cetrotide), have come into increasingly common use since their release in the last 3 years. This class of GnRH analogue has several potential advantages over GnRH agonists. Among these advantages are 1) shorter duration of injectable drug treatment, 2) decreased gonadotropin requirement per cycle, 3) improved patient convenience and 4) lower overall treatment cost. As clinicians gain experience with these drugs, optimal treatment paradigms will likely emerge. This review will discuss current strategies and potential applications for the GnRH antagonists.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Fertilization in Vitro
/
Gonadotropin-Releasing Hormone
Limits:
Female
/
Humans
Language:
En
Journal:
Minerva Ginecol
Year:
2003
Document type:
Article
Affiliation country:
United States